Brokerages predict that Crispr Therapeutics AG (NASDAQ:CRSP) will post earnings per share (EPS) of $0.04 for the current quarter, according to Zacks. Four analysts have made estimates for Crispr Therapeutics’ earnings. The lowest EPS estimate is $0.01 and the highest is $0.07. Crispr Therapeutics reported earnings of ($0.92) per share during the same quarter last year, which indicates a positive year over year growth rate of 104.3%. The company is scheduled to issue its next earnings results on Monday, February 24th.

On average, analysts expect that Crispr Therapeutics will report full year earnings of $0.65 per share for the current year, with EPS estimates ranging from $0.59 to $0.71. For the next year, analysts expect that the business will post earnings of ($4.68) per share, with EPS estimates ranging from ($5.38) to ($3.67). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. The company had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.

A number of equities analysts recently weighed in on CRSP shares. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a report on Friday. Zacks Investment Research cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Chardan Capital reissued a “buy” rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a research report on Monday, November 18th. Roth Capital boosted their price objective on shares of Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Finally, TheStreet upgraded shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. Crispr Therapeutics has an average rating of “Buy” and a consensus price target of $69.54.

In related news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the transaction, the director now owns 7,500 shares in the company, valued at approximately $412,500. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock valued at $3,620,760 in the last ninety days. Insiders own 21.40% of the company’s stock.

Several large investors have recently modified their holdings of the company. NEXT Financial Group Inc increased its stake in shares of Crispr Therapeutics by 915.0% during the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after purchasing an additional 549 shares during the period. Benjamin Edwards Inc. grew its holdings in Crispr Therapeutics by 96.4% in the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after buying an additional 268 shares in the last quarter. Coastal Investment Advisors Inc. acquired a new position in Crispr Therapeutics in the 3rd quarter valued at $26,000. US Bancorp DE increased its position in Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after buying an additional 526 shares during the period. Finally, BSW Wealth Partners bought a new position in Crispr Therapeutics during the 2nd quarter worth $39,000. Institutional investors own 49.81% of the company’s stock.

Shares of NASDAQ:CRSP traded up $1.66 during midday trading on Monday, hitting $72.37. The stock had a trading volume of 892,934 shares, compared to its average volume of 703,877. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The business’s 50-day simple moving average is $54.81 and its 200-day simple moving average is $47.38. The company has a market cap of $4.00 billion, a P/E ratio of -21.04 and a beta of 3.30.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Story: What is required to own or exchange cryptocurrency?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link